Effect of Omega 3 on Atrophic Vaginitis in Breast Cancer Survivors

Inclusion Criteria: * Woman with a history of breast cancer, stage 0, I, II, or III * At least 12 months from definitive surgical procedure (i.e. lumpectomy or mastectomy) * At least 3 months from completion of chemotherapy * Postmenopausal, defined as no menstrual cycle for 12 consecutive months, or surgical menopause * Have one or more stated symptoms of atrophic vaginitis, such as vaginal dryness, genital irritation/itching, genital pain, and/or dyspareunia * No current use of estrogen replacement therapy * If recent use of estrogen replacement therapy, off at least three months * No current use of estradiol-releasing vaginal ring or estradiol vaginal tablets; if recent use of these products, off at least 3 consecutive months * No evidence of disease (NED), any cancer other than breast cancer * No current use of oral omega 3 fatty acids or Vitamin E; if recent consistent use of these products, off at least six months; if sporadic use of these products, off at least 3 consecutive months * May be taking oral anti-estrogens or aromatase inhibitors, and/or biologic therapy * Must be willing to undergo venipuncture at 0, 3, and 6 months * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * No history of a bleeding tendency * No history of uncontrolled hypertension, heart disease or stroke * Hemoglobin \> 10 g/dL * Hematocrit \> 30% * White blood count \> 3.5 K/uL * Platelet count \> 100,000/mm\^3 * Fasting serum glucose \< 115 mg/dL * Total bilirubin \< 1.6 mg/dL * Transaminases alanine aminotransferase(ALT)and aspartate aminotransferase (AST)\< 1.5 x ULN (upper limit of normal) Exclusion Criteria: * Metastatic malignancy of any kind * Ongoing chemotherapy or radiation therapy (ongoing hormonal therapy and/or biologic therapy are allowed) * History of pelvic or genital radiation therapy * Use of Coumadin or other anticoagulants * Known, active pelvic, vaginal, or urinary tract infections * Current use of hormone replacement therapy, either systemic or local * Uncontrolled co-morbidities including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, unstable hypertension * Psychiatric illness/social situation that would limit adherence to study requirements * Consistent use of omega-3 fatty acid concentrates or capsules within the 6 months prior to entry on the study * Known sensitivity or allergy to fish oil or omega 3 fish products * Pregnant or nursing women * Subjects who cannot give an informed consent